PPT Slide
Results: Safe and well tolerated No drug related adverse events No major bleeding events (expect 5-20% w/other thrombolytics) No ICHs (expect 1-2% w/other thrombolytics) Little to no affect on clotting factors Expected consumption of some free alpha-2-macroglobulin
of Results: Anticipate publication of Phase 1 data in a medical journal in Q4 2003
Oral presentation of Phase 1 data by Dr. Jacob Cynamon of the Montefiore Medical Center at the AIM Symposium, Nov. 18th in NYC, titled “Alfimeprase: A Novel New Thrombolytic Agent That May Reduce Complications And Improve Efficacy”
Alfimeprase Phase 1 Successfully Completed